Abstract
The histamine H3 receptor is a pre-synaptic auto- and hetero-receptor that controls the release of histamine and a variety of other neurotransmitters in the brain. As such, modulation of the histamine H3 receptor is expected to affect wake via control of the release of histamine and to affect cognition via regulation of several other neurotransmitters including acetylcholine and norepinephrine. Over the last several years numerous pre-clinical studies have shown that histamine H3 antagonists promote wakefulness, improve cognition, and in some cases affect food intake. Based on the interest level generated from these early pharmacology studies, and following the cloning and expression of the human histamine H3 receptor, many pharmaceutical companies began drug discovery programs aimed at the identification of histamine H3 antagonists suitable for human clinical trials. These efforts have led to many new chemotypes, and several promising compounds have recently entered the clinic for a variety of conditions, including ADHD, Narcolepsy, EDS associated with Narcolepsy, Cognitive disorders and Schizophrenia. Recent efforts towards the identification and pharmacological characterization of novel histamine H3 antagonists will be discussed.
Keywords: Histamine, histamine H3, wake, cognition, histamine h3 antagonists/inverse agonists
Current Topics in Medicinal Chemistry
Title: Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents
Volume: 8 Issue: 11
Author(s): Emily M. Stocking and Michael A. Letavic
Affiliation:
Keywords: Histamine, histamine H3, wake, cognition, histamine h3 antagonists/inverse agonists
Abstract: The histamine H3 receptor is a pre-synaptic auto- and hetero-receptor that controls the release of histamine and a variety of other neurotransmitters in the brain. As such, modulation of the histamine H3 receptor is expected to affect wake via control of the release of histamine and to affect cognition via regulation of several other neurotransmitters including acetylcholine and norepinephrine. Over the last several years numerous pre-clinical studies have shown that histamine H3 antagonists promote wakefulness, improve cognition, and in some cases affect food intake. Based on the interest level generated from these early pharmacology studies, and following the cloning and expression of the human histamine H3 receptor, many pharmaceutical companies began drug discovery programs aimed at the identification of histamine H3 antagonists suitable for human clinical trials. These efforts have led to many new chemotypes, and several promising compounds have recently entered the clinic for a variety of conditions, including ADHD, Narcolepsy, EDS associated with Narcolepsy, Cognitive disorders and Schizophrenia. Recent efforts towards the identification and pharmacological characterization of novel histamine H3 antagonists will be discussed.
Export Options
About this article
Cite this article as:
Stocking M. Emily and Letavic A. Michael, Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents, Current Topics in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/156802608784936728
DOI https://dx.doi.org/10.2174/156802608784936728 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews Beyond Mitochondria, What Would be the Energy Source of the Cell?
Central Nervous System Agents in Medicinal Chemistry Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry Detection and Treatment of Alcohol-Induced Hypertension
Current Hypertension Reviews Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography
Current Radiopharmaceuticals Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View
Reviews on Recent Clinical Trials Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Statins and Portal Hypertension: A New Pharmacological Challenge
Current Vascular Pharmacology Eucommia Leaf Extract Induces BDNF Production in Rat Hypothalamus and Enhances Lipid Metabolism and Aerobic Glycolysis in Rat Liver
Current Molecular Pharmacology Meet Our Editorial Board Member
Current Hypertension Reviews The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Therapeutic Perspectives on Pancreatic Cancer
Current Cancer Drug Targets Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Current Topics in Medicinal Chemistry Transient Receptor Potential Channels and Dermatological Disorders
Current Topics in Medicinal Chemistry Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology